A Report of Pediatric Langerhans Cell Histiocytosis in a Hospital-Based Study

IF 0.4 Q4 ONCOLOGY

International Journal of Cancer Management Pub Date : 2024-05-07 DOI:10.5812/ijcm-146126

Javad Sabery Nejad, Ali Ebrahim Ahmadi, M. Tashvighi, N. Mehrvar, A. Mehrvar

{"title":"A Report of Pediatric Langerhans Cell Histiocytosis in a Hospital-Based Study","authors":"Javad Sabery Nejad, Ali Ebrahim Ahmadi, M. Tashvighi, N. Mehrvar, A. Mehrvar","doi":"10.5812/ijcm-146126","DOIUrl":null,"url":null,"abstract":"Background: The reports of Iranian Pediatric Langerhans Cell Histiocytosis (LCH) are rare and there is no specific survival rate for those cases. Objectives: This study was designed as a hospital-based project for evaluating the epidemiological data and survival rates of the mentioned patients. Methods: This was a cross-sectional descriptive study that enrolled patients younger than 15 years old with approved LCH malignancy. Data was gathered based on a unique questionnaire and analyzed by SPSS Software version 25. Results: There were 32 cases (male/female ratio = 0.88) who were categorized as high risk (n = 18), moderate (n = 9) and low risk (n = 5), respectively. The mean age of patients was 5.1 years and the common chief complaint in them was bone pain, with the skeleton site of involvement. The 5-years overall and event-free survival rates were 93.3% and 72.9%, respectively. Conclusions: The suggestion is to provide a national registry for pediatric LCH followed by designing future projects around affective genes on the treatment response of the mentioned patients. In that way, we can improve the survival rate of these patients and decrease mortality.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/ijcm-146126","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The reports of Iranian Pediatric Langerhans Cell Histiocytosis (LCH) are rare and there is no specific survival rate for those cases. Objectives: This study was designed as a hospital-based project for evaluating the epidemiological data and survival rates of the mentioned patients. Methods: This was a cross-sectional descriptive study that enrolled patients younger than 15 years old with approved LCH malignancy. Data was gathered based on a unique questionnaire and analyzed by SPSS Software version 25. Results: There were 32 cases (male/female ratio = 0.88) who were categorized as high risk (n = 18), moderate (n = 9) and low risk (n = 5), respectively. The mean age of patients was 5.1 years and the common chief complaint in them was bone pain, with the skeleton site of involvement. The 5-years overall and event-free survival rates were 93.3% and 72.9%, respectively. Conclusions: The suggestion is to provide a national registry for pediatric LCH followed by designing future projects around affective genes on the treatment response of the mentioned patients. In that way, we can improve the survival rate of these patients and decrease mortality.

查看原文本刊更多论文

一项基于医院的小儿朗格汉斯细胞组织细胞增生症研究报告

背景：伊朗小儿朗格汉斯细胞组织细胞增生症（Langerhans Cell Histiocytosis，LCH）的报道非常罕见，也没有具体的存活率。研究目的本研究是一项以医院为基础的项目，旨在评估上述患者的流行病学数据和存活率。方法：这是一项横断面描述性研究：这是一项横断面描述性研究，研究对象为年龄小于 15 岁、患有经批准的 LCH 恶性肿瘤的患者。数据收集基于一份独特的调查问卷，并通过 SPSS 软件 25 版进行分析。研究结果32例患者（男女比例=0.88）分别被分为高危（18例）、中危（9例）和低危（5例）。患者平均年龄为 5.1 岁，常见主诉为骨痛，受累部位为骨骼。5年总生存率和无事件生存率分别为93.3%和72.9%。结论是建议为儿科 LCH 建立一个全国登记册，然后围绕影响上述患者治疗反应的基因设计未来的项目。这样，我们就能提高这些患者的生存率，降低死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Cancer Management ONCOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： International Journal of Cancer Management (IJCM) publishes peer-reviewed original studies and reviews on cancer etiology, epidemiology and risk factors, novel approach to cancer management including prevention, diagnosis, surgery, radiotherapy, medical oncology, and issues regarding cancer survivorship and palliative care. The scope spans the spectrum of cancer research from the laboratory to the clinic, with special emphasis on translational cancer research that bridge the laboratory and clinic. We also consider original case reports that expand clinical cancer knowledge and convey important best practice messages.